Institutional shares held 91.7 Million
1.33M calls
549K puts
Total value of holdings $1.85B
$26.8M calls
$11.1M puts
Market Cap $2.11B
105,849,000 Shares Out.
Institutional ownership 86.68%
# of Institutions 293


Latest Institutional Activity in ARWR

Top Purchases

Q3 2024
Assenagon Asset Management S.A. Shares Held: 293K ($5.86M)
Q3 2024
Abrdn PLC Shares Held: 401K ($8.01M)
Q3 2024
International Assets Investment Management, LLC Shares Held: 74.4K ($1.49M)
Q3 2024
Buffington Mohr Mc Neal Shares Held: 30K ($599K)
Q3 2024
Sg Americas Securities, LLC Shares Held: 35.2K ($703K)

Top Sells

Q3 2024
Cwm, LLC Shares Held: 2.15K ($43K)
Q3 2024
New York State Common Retirement Fund Shares Held: 37K ($739K)
Q3 2024
Exchange Traded Concepts, LLC Shares Held: 40.3K ($805K)
Q3 2024
Silicon Valley Capital Partners Shares Held: 0 ($0)
Q3 2024
Yousif Capital Management, LLC Shares Held: 47.5K ($948K)

About ARWR

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.


Insider Transactions at ARWR

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
535K Shares
From 13 Insiders
Open market or private purchase 3K shares
Exercise of conversion of derivative security 57.5K shares
Grant, award, or other acquisition 475K shares
Sell / Disposition
299K Shares
From 10 Insiders
Open market or private sale 299K shares

Track Institutional and Insider Activities on ARWR

Follow ARROWHEAD PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ARWR shares.

Notify only if

Insider Trading

Get notified when an Arrowhead Pharmaceuticals, Inc. insider buys or sells ARWR shares.

Notify only if

News

Receive news related to ARROWHEAD PHARMACEUTICALS, INC.

Track Activities on ARWR